nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—ABCB1—Levothyroxine—hypothyroidism	0.0111	0.28	CbGbCtD
Crizotinib—ABCB1—Liothyronine—hypothyroidism	0.0111	0.28	CbGbCtD
Crizotinib—ABCB1—Liotrix—hypothyroidism	0.0109	0.273	CbGbCtD
Crizotinib—CYP3A4—Levothyroxine—hypothyroidism	0.00667	0.168	CbGbCtD
Crizotinib—Abscess—Liotrix—hypothyroidism	0.00494	0.049	CcSEcCtD
Crizotinib—Arrhythmia—Liothyronine—hypothyroidism	0.00485	0.0482	CcSEcCtD
Crizotinib—Fluid retention—Liotrix—hypothyroidism	0.00371	0.0368	CcSEcCtD
Crizotinib—Muscular weakness—Dextrothyroxine—hypothyroidism	0.0034	0.0338	CcSEcCtD
Crizotinib—Muscular weakness—Levothyroxine—hypothyroidism	0.0034	0.0338	CcSEcCtD
Crizotinib—Sepsis—Liotrix—hypothyroidism	0.00339	0.0337	CcSEcCtD
Crizotinib—Body temperature increased—Liothyronine—hypothyroidism	0.00305	0.0303	CcSEcCtD
Crizotinib—Weight decreased—Levothyroxine—hypothyroidism	0.00301	0.0299	CcSEcCtD
Crizotinib—Weight decreased—Dextrothyroxine—hypothyroidism	0.00301	0.0299	CcSEcCtD
Crizotinib—Hypokalaemia—Liotrix—hypothyroidism	0.00258	0.0256	CcSEcCtD
Crizotinib—Muscular weakness—Liotrix—hypothyroidism	0.0025	0.0248	CcSEcCtD
Crizotinib—Arrhythmia—Levothyroxine—hypothyroidism	0.00238	0.0237	CcSEcCtD
Crizotinib—Arrhythmia—Dextrothyroxine—hypothyroidism	0.00238	0.0237	CcSEcCtD
Crizotinib—Weight decreased—Liotrix—hypothyroidism	0.00222	0.022	CcSEcCtD
Crizotinib—Hypoaesthesia—Liotrix—hypothyroidism	0.00195	0.0194	CcSEcCtD
Crizotinib—Shock—Levothyroxine—hypothyroidism	0.00186	0.0185	CcSEcCtD
Crizotinib—Shock—Dextrothyroxine—hypothyroidism	0.00186	0.0185	CcSEcCtD
Crizotinib—Arrhythmia—Liotrix—hypothyroidism	0.00175	0.0174	CcSEcCtD
Crizotinib—Dyspnoea—Dextrothyroxine—hypothyroidism	0.00169	0.0168	CcSEcCtD
Crizotinib—Dyspnoea—Levothyroxine—hypothyroidism	0.00169	0.0168	CcSEcCtD
Crizotinib—Dysgeusia—Liotrix—hypothyroidism	0.00167	0.0166	CcSEcCtD
Crizotinib—Fatigue—Dextrothyroxine—hypothyroidism	0.00163	0.0162	CcSEcCtD
Crizotinib—Fatigue—Levothyroxine—hypothyroidism	0.00163	0.0162	CcSEcCtD
Crizotinib—Vision blurred—Liotrix—hypothyroidism	0.00161	0.016	CcSEcCtD
Crizotinib—Syncope—Liotrix—hypothyroidism	0.00153	0.0152	CcSEcCtD
Crizotinib—Loss of consciousness—Liotrix—hypothyroidism	0.0015	0.0149	CcSEcCtD
Crizotinib—Body temperature increased—Dextrothyroxine—hypothyroidism	0.0015	0.0149	CcSEcCtD
Crizotinib—Body temperature increased—Levothyroxine—hypothyroidism	0.0015	0.0149	CcSEcCtD
Crizotinib—Oedema—Liotrix—hypothyroidism	0.00139	0.0138	CcSEcCtD
Crizotinib—Infection—Liotrix—hypothyroidism	0.00138	0.0138	CcSEcCtD
Crizotinib—Shock—Liotrix—hypothyroidism	0.00137	0.0136	CcSEcCtD
Crizotinib—Asthenia—Levothyroxine—hypothyroidism	0.00136	0.0135	CcSEcCtD
Crizotinib—Asthenia—Dextrothyroxine—hypothyroidism	0.00136	0.0135	CcSEcCtD
Crizotinib—Diarrhoea—Levothyroxine—hypothyroidism	0.0013	0.0129	CcSEcCtD
Crizotinib—Diarrhoea—Dextrothyroxine—hypothyroidism	0.0013	0.0129	CcSEcCtD
Crizotinib—Paraesthesia—Liotrix—hypothyroidism	0.00125	0.0124	CcSEcCtD
Crizotinib—Dyspnoea—Liotrix—hypothyroidism	0.00124	0.0123	CcSEcCtD
Crizotinib—Decreased appetite—Liotrix—hypothyroidism	0.00121	0.012	CcSEcCtD
Crizotinib—Vomiting—Levothyroxine—hypothyroidism	0.0012	0.012	CcSEcCtD
Crizotinib—Vomiting—Dextrothyroxine—hypothyroidism	0.0012	0.012	CcSEcCtD
Crizotinib—Fatigue—Liotrix—hypothyroidism	0.0012	0.0119	CcSEcCtD
Crizotinib—Rash—Dextrothyroxine—hypothyroidism	0.00119	0.0119	CcSEcCtD
Crizotinib—Rash—Levothyroxine—hypothyroidism	0.00119	0.0119	CcSEcCtD
Crizotinib—Dermatitis—Levothyroxine—hypothyroidism	0.00119	0.0119	CcSEcCtD
Crizotinib—Dermatitis—Dextrothyroxine—hypothyroidism	0.00119	0.0119	CcSEcCtD
Crizotinib—Constipation—Liotrix—hypothyroidism	0.00119	0.0118	CcSEcCtD
Crizotinib—Nausea—Levothyroxine—hypothyroidism	0.00113	0.0112	CcSEcCtD
Crizotinib—Nausea—Dextrothyroxine—hypothyroidism	0.00113	0.0112	CcSEcCtD
Crizotinib—Body temperature increased—Liotrix—hypothyroidism	0.0011	0.0109	CcSEcCtD
Crizotinib—Asthenia—Liotrix—hypothyroidism	0.001	0.00993	CcSEcCtD
Crizotinib—Diarrhoea—Liotrix—hypothyroidism	0.000953	0.00947	CcSEcCtD
Crizotinib—Dizziness—Liotrix—hypothyroidism	0.000921	0.00916	CcSEcCtD
Crizotinib—Vomiting—Liotrix—hypothyroidism	0.000886	0.0088	CcSEcCtD
Crizotinib—Rash—Liotrix—hypothyroidism	0.000879	0.00873	CcSEcCtD
Crizotinib—Dermatitis—Liotrix—hypothyroidism	0.000878	0.00872	CcSEcCtD
Crizotinib—Nausea—Liotrix—hypothyroidism	0.000828	0.00822	CcSEcCtD
Crizotinib—TNK2—cerebellum—hypothyroidism	0.000651	0.00129	CbGeAlD
Crizotinib—IGF1R—cerebellum—hypothyroidism	0.000651	0.00129	CbGeAlD
Crizotinib—SLK—pituitary gland—hypothyroidism	0.000649	0.00129	CbGeAlD
Crizotinib—STK3—liver—hypothyroidism	0.000648	0.00129	CbGeAlD
Crizotinib—TIE1—liver—hypothyroidism	0.000648	0.00129	CbGeAlD
Crizotinib—MAP3K2—adrenal gland—hypothyroidism	0.000646	0.00128	CbGeAlD
Crizotinib—MAP3K2—blood—hypothyroidism	0.000646	0.00128	CbGeAlD
Crizotinib—MERTK—testis—hypothyroidism	0.000645	0.00128	CbGeAlD
Crizotinib—EPHB4—pituitary gland—hypothyroidism	0.000645	0.00128	CbGeAlD
Crizotinib—MAP4K2—cerebellum—hypothyroidism	0.000642	0.00127	CbGeAlD
Crizotinib—PTK2B—female gonad—hypothyroidism	0.000641	0.00127	CbGeAlD
Crizotinib—JAK2—pituitary gland—hypothyroidism	0.00064	0.00127	CbGeAlD
Crizotinib—STK10—cardiovascular system—hypothyroidism	0.000638	0.00126	CbGeAlD
Crizotinib—EPHA4—thyroid gland—hypothyroidism	0.000636	0.00126	CbGeAlD
Crizotinib—RIPK2—female gonad—hypothyroidism	0.000635	0.00126	CbGeAlD
Crizotinib—TAOK3—cardiovascular system—hypothyroidism	0.000635	0.00126	CbGeAlD
Crizotinib—STK3—cerebellum—hypothyroidism	0.000633	0.00126	CbGeAlD
Crizotinib—TIE1—cerebellum—hypothyroidism	0.000633	0.00126	CbGeAlD
Crizotinib—TBK1—adrenal gland—hypothyroidism	0.000633	0.00125	CbGeAlD
Crizotinib—PTK2—adrenal gland—hypothyroidism	0.000633	0.00125	CbGeAlD
Crizotinib—TBK1—blood—hypothyroidism	0.000633	0.00125	CbGeAlD
Crizotinib—PTK2—blood—hypothyroidism	0.000633	0.00125	CbGeAlD
Crizotinib—EPHA2—pituitary gland—hypothyroidism	0.000632	0.00125	CbGeAlD
Crizotinib—MAP4K5—gonad—hypothyroidism	0.000632	0.00125	CbGeAlD
Crizotinib—MAP3K3—gonad—hypothyroidism	0.000632	0.00125	CbGeAlD
Crizotinib—AURKA—liver—hypothyroidism	0.000632	0.00125	CbGeAlD
Crizotinib—LIMK2—testis—hypothyroidism	0.000631	0.00125	CbGeAlD
Crizotinib—TYK2—adrenal gland—hypothyroidism	0.000628	0.00125	CbGeAlD
Crizotinib—NUAK2—testis—hypothyroidism	0.000628	0.00125	CbGeAlD
Crizotinib—TYK2—blood—hypothyroidism	0.000628	0.00125	CbGeAlD
Crizotinib—TESK1—liver—hypothyroidism	0.000627	0.00124	CbGeAlD
Crizotinib—MAP3K12—testis—hypothyroidism	0.000624	0.00124	CbGeAlD
Crizotinib—FLT3—testis—hypothyroidism	0.000624	0.00124	CbGeAlD
Crizotinib—ACVR1—testis—hypothyroidism	0.000624	0.00124	CbGeAlD
Crizotinib—MAP3K2—thyroid gland—hypothyroidism	0.000623	0.00124	CbGeAlD
Crizotinib—IRAK1—adrenal gland—hypothyroidism	0.00062	0.00123	CbGeAlD
Crizotinib—IRAK1—blood—hypothyroidism	0.00062	0.00123	CbGeAlD
Crizotinib—SRC—cardiovascular system—hypothyroidism	0.000619	0.00123	CbGeAlD
Crizotinib—TEK—pituitary gland—hypothyroidism	0.000617	0.00122	CbGeAlD
Crizotinib—MAP3K3—pituitary gland—hypothyroidism	0.000617	0.00122	CbGeAlD
Crizotinib—MAP4K5—pituitary gland—hypothyroidism	0.000617	0.00122	CbGeAlD
Crizotinib—EPHA4—female gonad—hypothyroidism	0.000614	0.00122	CbGeAlD
Crizotinib—TESK1—cerebellum—hypothyroidism	0.000612	0.00121	CbGeAlD
Crizotinib—STK35—testis—hypothyroidism	0.000611	0.00121	CbGeAlD
Crizotinib—TBK1—thyroid gland—hypothyroidism	0.000611	0.00121	CbGeAlD
Crizotinib—PTK2—thyroid gland—hypothyroidism	0.000611	0.00121	CbGeAlD
Crizotinib—MERTK—liver—hypothyroidism	0.00061	0.00121	CbGeAlD
Crizotinib—CSF1R—adrenal cortex—hypothyroidism	0.000609	0.00121	CbGeAlD
Crizotinib—RPS6KB1—adrenal gland—hypothyroidism	0.000609	0.00121	CbGeAlD
Crizotinib—RPS6KB1—blood—hypothyroidism	0.000608	0.00121	CbGeAlD
Crizotinib—TYK2—thyroid gland—hypothyroidism	0.000606	0.0012	CbGeAlD
Crizotinib—FGR—adrenal gland—hypothyroidism	0.000605	0.0012	CbGeAlD
Crizotinib—LCK—adrenal gland—hypothyroidism	0.000605	0.0012	CbGeAlD
Crizotinib—LCK—blood—hypothyroidism	0.000605	0.0012	CbGeAlD
Crizotinib—FGR—blood—hypothyroidism	0.000605	0.0012	CbGeAlD
Crizotinib—AXL—adrenal gland—hypothyroidism	0.000602	0.00119	CbGeAlD
Crizotinib—MAP3K2—female gonad—hypothyroidism	0.000602	0.00119	CbGeAlD
Crizotinib—IRAK1—thyroid gland—hypothyroidism	0.000599	0.00119	CbGeAlD
Crizotinib—LIMK2—liver—hypothyroidism	0.000596	0.00118	CbGeAlD
Crizotinib—ABL2—testis—hypothyroidism	0.000596	0.00118	CbGeAlD
Crizotinib—MERTK—cerebellum—hypothyroidism	0.000595	0.00118	CbGeAlD
Crizotinib—NUAK2—liver—hypothyroidism	0.000594	0.00118	CbGeAlD
Crizotinib—PTK2—female gonad—hypothyroidism	0.00059	0.00117	CbGeAlD
Crizotinib—TBK1—female gonad—hypothyroidism	0.00059	0.00117	CbGeAlD
Crizotinib—MAP3K12—liver—hypothyroidism	0.00059	0.00117	CbGeAlD
Crizotinib—FLT3—liver—hypothyroidism	0.00059	0.00117	CbGeAlD
Crizotinib—ACVR1—liver—hypothyroidism	0.00059	0.00117	CbGeAlD
Crizotinib—EPHB6—pituitary gland—hypothyroidism	0.000589	0.00117	CbGeAlD
Crizotinib—CSF1R—heart—hypothyroidism	0.000589	0.00117	CbGeAlD
Crizotinib—BMP2K—testis—hypothyroidism	0.000588	0.00117	CbGeAlD
Crizotinib—RPS6KB1—thyroid gland—hypothyroidism	0.000587	0.00116	CbGeAlD
Crizotinib—TYK2—female gonad—hypothyroidism	0.000586	0.00116	CbGeAlD
Crizotinib—YES1—gonad—hypothyroidism	0.000584	0.00116	CbGeAlD
Crizotinib—LCK—thyroid gland—hypothyroidism	0.000584	0.00116	CbGeAlD
Crizotinib—FGR—thyroid gland—hypothyroidism	0.000584	0.00116	CbGeAlD
Crizotinib—LIMK2—cerebellum—hypothyroidism	0.000582	0.00116	CbGeAlD
Crizotinib—AXL—thyroid gland—hypothyroidism	0.000581	0.00115	CbGeAlD
Crizotinib—NUAK2—cerebellum—hypothyroidism	0.00058	0.00115	CbGeAlD
Crizotinib—SLK—adrenal gland—hypothyroidism	0.00058	0.00115	CbGeAlD
Crizotinib—SLK—blood—hypothyroidism	0.00058	0.00115	CbGeAlD
Crizotinib—STK10—gonad—hypothyroidism	0.000579	0.00115	CbGeAlD
Crizotinib—IRAK1—female gonad—hypothyroidism	0.000578	0.00115	CbGeAlD
Crizotinib—STK35—liver—hypothyroidism	0.000578	0.00115	CbGeAlD
Crizotinib—FLT3—cerebellum—hypothyroidism	0.000576	0.00114	CbGeAlD
Crizotinib—ACVR1—cerebellum—hypothyroidism	0.000576	0.00114	CbGeAlD
Crizotinib—MAP3K12—cerebellum—hypothyroidism	0.000576	0.00114	CbGeAlD
Crizotinib—EPHB4—adrenal gland—hypothyroidism	0.000576	0.00114	CbGeAlD
Crizotinib—EPHB4—blood—hypothyroidism	0.000576	0.00114	CbGeAlD
Crizotinib—JAK2—adrenal gland—hypothyroidism	0.000572	0.00113	CbGeAlD
Crizotinib—JAK2—blood—hypothyroidism	0.000572	0.00113	CbGeAlD
Crizotinib—YES1—pituitary gland—hypothyroidism	0.00057	0.00113	CbGeAlD
Crizotinib—PTK2B—testis—hypothyroidism	0.000568	0.00113	CbGeAlD
Crizotinib—RPS6KB1—female gonad—hypothyroidism	0.000567	0.00113	CbGeAlD
Crizotinib—EPHA2—adrenal gland—hypothyroidism	0.000565	0.00112	CbGeAlD
Crizotinib—EPHA2—blood—hypothyroidism	0.000565	0.00112	CbGeAlD
Crizotinib—STK35—cerebellum—hypothyroidism	0.000564	0.00112	CbGeAlD
Crizotinib—LCK—female gonad—hypothyroidism	0.000564	0.00112	CbGeAlD
Crizotinib—FGR—female gonad—hypothyroidism	0.000564	0.00112	CbGeAlD
Crizotinib—RIPK2—testis—hypothyroidism	0.000564	0.00112	CbGeAlD
Crizotinib—ABL2—liver—hypothyroidism	0.000563	0.00112	CbGeAlD
Crizotinib—TAOK3—pituitary gland—hypothyroidism	0.000562	0.00112	CbGeAlD
Crizotinib—AXL—female gonad—hypothyroidism	0.000562	0.00111	CbGeAlD
Crizotinib—SRC—gonad—hypothyroidism	0.000562	0.00111	CbGeAlD
Crizotinib—SLK—thyroid gland—hypothyroidism	0.00056	0.00111	CbGeAlD
Crizotinib—BMP2K—liver—hypothyroidism	0.000556	0.0011	CbGeAlD
Crizotinib—CSF1R—cardiovascular system—hypothyroidism	0.000556	0.0011	CbGeAlD
Crizotinib—EPHB4—thyroid gland—hypothyroidism	0.000556	0.0011	CbGeAlD
Crizotinib—JAK2—thyroid gland—hypothyroidism	0.000552	0.00109	CbGeAlD
Crizotinib—TEK—adrenal gland—hypothyroidism	0.000551	0.00109	CbGeAlD
Crizotinib—MAP4K5—adrenal gland—hypothyroidism	0.000551	0.00109	CbGeAlD
Crizotinib—MAP3K3—adrenal gland—hypothyroidism	0.000551	0.00109	CbGeAlD
Crizotinib—MAP4K5—blood—hypothyroidism	0.000551	0.00109	CbGeAlD
Crizotinib—MAP3K3—blood—hypothyroidism	0.000551	0.00109	CbGeAlD
Crizotinib—TEK—blood—hypothyroidism	0.000551	0.00109	CbGeAlD
Crizotinib—ABL2—cerebellum—hypothyroidism	0.00055	0.00109	CbGeAlD
Crizotinib—EPHA2—thyroid gland—hypothyroidism	0.000545	0.00108	CbGeAlD
Crizotinib—EPHA4—testis—hypothyroidism	0.000545	0.00108	CbGeAlD
Crizotinib—BMP2K—cerebellum—hypothyroidism	0.000543	0.00108	CbGeAlD
Crizotinib—SLK—female gonad—hypothyroidism	0.000541	0.00107	CbGeAlD
Crizotinib—PTK2B—liver—hypothyroidism	0.000537	0.00107	CbGeAlD
Crizotinib—EPHB4—female gonad—hypothyroidism	0.000537	0.00106	CbGeAlD
Crizotinib—MAP3K2—testis—hypothyroidism	0.000534	0.00106	CbGeAlD
Crizotinib—JAK2—female gonad—hypothyroidism	0.000533	0.00106	CbGeAlD
Crizotinib—RIPK2—liver—hypothyroidism	0.000533	0.00106	CbGeAlD
Crizotinib—MAP3K3—thyroid gland—hypothyroidism	0.000532	0.00105	CbGeAlD
Crizotinib—TEK—thyroid gland—hypothyroidism	0.000532	0.00105	CbGeAlD
Crizotinib—MAP4K5—thyroid gland—hypothyroidism	0.000532	0.00105	CbGeAlD
Crizotinib—EPHA2—female gonad—hypothyroidism	0.000527	0.00104	CbGeAlD
Crizotinib—EPHB6—adrenal gland—hypothyroidism	0.000527	0.00104	CbGeAlD
Crizotinib—EPHB6—blood—hypothyroidism	0.000527	0.00104	CbGeAlD
Crizotinib—PTK2B—cerebellum—hypothyroidism	0.000525	0.00104	CbGeAlD
Crizotinib—PTK2—testis—hypothyroidism	0.000523	0.00104	CbGeAlD
Crizotinib—TBK1—testis—hypothyroidism	0.000523	0.00104	CbGeAlD
Crizotinib—RIPK2—cerebellum—hypothyroidism	0.00052	0.00103	CbGeAlD
Crizotinib—TYK2—testis—hypothyroidism	0.00052	0.00103	CbGeAlD
Crizotinib—MAP4K5—female gonad—hypothyroidism	0.000514	0.00102	CbGeAlD
Crizotinib—MAP3K3—female gonad—hypothyroidism	0.000514	0.00102	CbGeAlD
Crizotinib—TEK—female gonad—hypothyroidism	0.000514	0.00102	CbGeAlD
Crizotinib—IRAK1—testis—hypothyroidism	0.000513	0.00102	CbGeAlD
Crizotinib—YES1—adrenal gland—hypothyroidism	0.000509	0.00101	CbGeAlD
Crizotinib—YES1—blood—hypothyroidism	0.000509	0.00101	CbGeAlD
Crizotinib—EPHB6—thyroid gland—hypothyroidism	0.000508	0.00101	CbGeAlD
Crizotinib—MAP3K2—liver—hypothyroidism	0.000505	0.001	CbGeAlD
Crizotinib—STK10—adrenal gland—hypothyroidism	0.000504	0.001	CbGeAlD
Crizotinib—CSF1R—gonad—hypothyroidism	0.000504	0.001	CbGeAlD
Crizotinib—STK10—blood—hypothyroidism	0.000504	0.001	CbGeAlD
Crizotinib—RPS6KB1—testis—hypothyroidism	0.000503	0.000998	CbGeAlD
Crizotinib—EPHA4—cerebellum—hypothyroidism	0.000503	0.000998	CbGeAlD
Crizotinib—TAOK3—adrenal gland—hypothyroidism	0.000502	0.000996	CbGeAlD
Crizotinib—TAOK3—blood—hypothyroidism	0.000502	0.000996	CbGeAlD
Crizotinib—LCK—testis—hypothyroidism	0.0005	0.000992	CbGeAlD
Crizotinib—FGR—testis—hypothyroidism	0.0005	0.000992	CbGeAlD
Crizotinib—AXL—testis—hypothyroidism	0.000498	0.000988	CbGeAlD
Crizotinib—TBK1—liver—hypothyroidism	0.000495	0.000981	CbGeAlD
Crizotinib—PTK2—liver—hypothyroidism	0.000495	0.000981	CbGeAlD
Crizotinib—MAP3K2—cerebellum—hypothyroidism	0.000493	0.000979	CbGeAlD
Crizotinib—CSF1R—pituitary gland—hypothyroidism	0.000492	0.000976	CbGeAlD
Crizotinib—TYK2—liver—hypothyroidism	0.000491	0.000975	CbGeAlD
Crizotinib—YES1—thyroid gland—hypothyroidism	0.000491	0.000974	CbGeAlD
Crizotinib—EPHB6—female gonad—hypothyroidism	0.000491	0.000974	CbGeAlD
Crizotinib—SRC—adrenal gland—hypothyroidism	0.00049	0.000971	CbGeAlD
Crizotinib—SRC—blood—hypothyroidism	0.000489	0.000971	CbGeAlD
Crizotinib—STK10—thyroid gland—hypothyroidism	0.000487	0.000965	CbGeAlD
Crizotinib—IRAK1—liver—hypothyroidism	0.000485	0.000962	CbGeAlD
Crizotinib—TAOK3—thyroid gland—hypothyroidism	0.000485	0.000962	CbGeAlD
Crizotinib—TBK1—cerebellum—hypothyroidism	0.000483	0.000958	CbGeAlD
Crizotinib—PTK2—cerebellum—hypothyroidism	0.000483	0.000958	CbGeAlD
Crizotinib—ABL1—adrenal cortex—hypothyroidism	0.000481	0.000955	CbGeAlD
Crizotinib—TYK2—cerebellum—hypothyroidism	0.00048	0.000952	CbGeAlD
Crizotinib—SLK—testis—hypothyroidism	0.00048	0.000951	CbGeAlD
Crizotinib—EPHB4—testis—hypothyroidism	0.000476	0.000944	CbGeAlD
Crizotinib—RPS6KB1—liver—hypothyroidism	0.000476	0.000944	CbGeAlD
Crizotinib—YES1—female gonad—hypothyroidism	0.000475	0.000941	CbGeAlD
Crizotinib—IRAK1—cerebellum—hypothyroidism	0.000474	0.00094	CbGeAlD
Crizotinib—LCK—liver—hypothyroidism	0.000473	0.000938	CbGeAlD
Crizotinib—FGR—liver—hypothyroidism	0.000473	0.000938	CbGeAlD
Crizotinib—JAK2—testis—hypothyroidism	0.000473	0.000938	CbGeAlD
Crizotinib—SRC—thyroid gland—hypothyroidism	0.000472	0.000937	CbGeAlD
Crizotinib—AXL—liver—hypothyroidism	0.000471	0.000934	CbGeAlD
Crizotinib—STK10—female gonad—hypothyroidism	0.00047	0.000933	CbGeAlD
Crizotinib—TAOK3—female gonad—hypothyroidism	0.000468	0.000929	CbGeAlD
Crizotinib—EPHA2—testis—hypothyroidism	0.000467	0.000927	CbGeAlD
Crizotinib—ABL1—heart—hypothyroidism	0.000465	0.000923	CbGeAlD
Crizotinib—RPS6KB1—cerebellum—hypothyroidism	0.000465	0.000922	CbGeAlD
Crizotinib—AXL—cerebellum—hypothyroidism	0.00046	0.000913	CbGeAlD
Crizotinib—SRC—female gonad—hypothyroidism	0.000456	0.000905	CbGeAlD
Crizotinib—MAP3K3—testis—hypothyroidism	0.000456	0.000904	CbGeAlD
Crizotinib—MAP4K5—testis—hypothyroidism	0.000456	0.000904	CbGeAlD
Crizotinib—TEK—testis—hypothyroidism	0.000456	0.000904	CbGeAlD
Crizotinib—SLK—liver—hypothyroidism	0.000453	0.000899	CbGeAlD
Crizotinib—EPHB4—liver—hypothyroidism	0.00045	0.000893	CbGeAlD
Crizotinib—JAK2—liver—hypothyroidism	0.000447	0.000887	CbGeAlD
Crizotinib—SLK—cerebellum—hypothyroidism	0.000443	0.000879	CbGeAlD
Crizotinib—EPHA2—liver—hypothyroidism	0.000442	0.000876	CbGeAlD
Crizotinib—EPHB4—cerebellum—hypothyroidism	0.00044	0.000872	CbGeAlD
Crizotinib—CSF1R—adrenal gland—hypothyroidism	0.00044	0.000872	CbGeAlD
Crizotinib—CSF1R—blood—hypothyroidism	0.000439	0.000872	CbGeAlD
Crizotinib—ABL1—cardiovascular system—hypothyroidism	0.000439	0.000871	CbGeAlD
Crizotinib—JAK2—cerebellum—hypothyroidism	0.000437	0.000866	CbGeAlD
Crizotinib—EPHB6—testis—hypothyroidism	0.000436	0.000864	CbGeAlD
Crizotinib—TEK—liver—hypothyroidism	0.000431	0.000855	CbGeAlD
Crizotinib—MAP3K3—liver—hypothyroidism	0.000431	0.000855	CbGeAlD
Crizotinib—MAP4K5—liver—hypothyroidism	0.000431	0.000855	CbGeAlD
Crizotinib—CSF1R—thyroid gland—hypothyroidism	0.000424	0.000841	CbGeAlD
Crizotinib—MAP4K5—cerebellum—hypothyroidism	0.000421	0.000835	CbGeAlD
Crizotinib—MAP3K3—cerebellum—hypothyroidism	0.000421	0.000835	CbGeAlD
Crizotinib—TEK—cerebellum—hypothyroidism	0.000421	0.000835	CbGeAlD
Crizotinib—YES1—testis—hypothyroidism	0.000421	0.000835	CbGeAlD
Crizotinib—STK10—testis—hypothyroidism	0.000417	0.000827	CbGeAlD
Crizotinib—TAOK3—testis—hypothyroidism	0.000415	0.000824	CbGeAlD
Crizotinib—CSF1R—female gonad—hypothyroidism	0.00041	0.000813	CbGeAlD
Crizotinib—SRC—testis—hypothyroidism	0.000405	0.000803	CbGeAlD
Crizotinib—EPHB6—cerebellum—hypothyroidism	0.000402	0.000798	CbGeAlD
Crizotinib—ABL1—gonad—hypothyroidism	0.000399	0.000791	CbGeAlD
Crizotinib—YES1—liver—hypothyroidism	0.000398	0.000789	CbGeAlD
Crizotinib—STK10—liver—hypothyroidism	0.000394	0.000782	CbGeAlD
Crizotinib—TAOK3—liver—hypothyroidism	0.000393	0.000779	CbGeAlD
Crizotinib—ABL1—pituitary gland—hypothyroidism	0.000389	0.000771	CbGeAlD
Crizotinib—YES1—cerebellum—hypothyroidism	0.000389	0.000771	CbGeAlD
Crizotinib—STK10—cerebellum—hypothyroidism	0.000385	0.000764	CbGeAlD
Crizotinib—TAOK3—cerebellum—hypothyroidism	0.000384	0.000761	CbGeAlD
Crizotinib—SRC—liver—hypothyroidism	0.000383	0.000759	CbGeAlD
Crizotinib—SRC—cerebellum—hypothyroidism	0.000374	0.000742	CbGeAlD
Crizotinib—CSF1R—testis—hypothyroidism	0.000363	0.000721	CbGeAlD
Crizotinib—ABL1—adrenal gland—hypothyroidism	0.000347	0.000689	CbGeAlD
Crizotinib—ABL1—blood—hypothyroidism	0.000347	0.000689	CbGeAlD
Crizotinib—CSF1R—liver—hypothyroidism	0.000344	0.000682	CbGeAlD
Crizotinib—CSF1R—cerebellum—hypothyroidism	0.000336	0.000666	CbGeAlD
Crizotinib—ABL1—thyroid gland—hypothyroidism	0.000335	0.000665	CbGeAlD
Crizotinib—ABL1—female gonad—hypothyroidism	0.000324	0.000643	CbGeAlD
Crizotinib—ABL1—testis—hypothyroidism	0.000287	0.00057	CbGeAlD
Crizotinib—ABL1—liver—hypothyroidism	0.000272	0.000539	CbGeAlD
Crizotinib—ABL1—cerebellum—hypothyroidism	0.000265	0.000526	CbGeAlD
Crizotinib—CYP3A5—blood—hypothyroidism	0.000203	0.000403	CbGeAlD
Crizotinib—CYP3A5—female gonad—hypothyroidism	0.00019	0.000376	CbGeAlD
Crizotinib—CYP3A5—liver—hypothyroidism	0.000159	0.000315	CbGeAlD
Crizotinib—CYP3A4—blood—hypothyroidism	0.000153	0.000303	CbGeAlD
Crizotinib—ABCB1—adrenal cortex—hypothyroidism	0.00015	0.000297	CbGeAlD
Crizotinib—ABCB1—heart—hypothyroidism	0.000145	0.000287	CbGeAlD
Crizotinib—ABCB1—cardiovascular system—hypothyroidism	0.000137	0.000271	CbGeAlD
Crizotinib—ABCB1—gonad—hypothyroidism	0.000124	0.000246	CbGeAlD
Crizotinib—ABCB1—pituitary gland—hypothyroidism	0.000121	0.00024	CbGeAlD
Crizotinib—CYP3A4—liver—hypothyroidism	0.000119	0.000237	CbGeAlD
Crizotinib—ABCB1—adrenal gland—hypothyroidism	0.000108	0.000214	CbGeAlD
Crizotinib—ABCB1—blood—hypothyroidism	0.000108	0.000214	CbGeAlD
Crizotinib—ABCB1—thyroid gland—hypothyroidism	0.000104	0.000207	CbGeAlD
Crizotinib—ABCB1—female gonad—hypothyroidism	0.000101	0.0002	CbGeAlD
Crizotinib—ABCB1—testis—hypothyroidism	8.93e-05	0.000177	CbGeAlD
Crizotinib—ABCB1—liver—hypothyroidism	8.45e-05	0.000168	CbGeAlD
Crizotinib—ABCB1—cerebellum—hypothyroidism	8.25e-05	0.000164	CbGeAlD
Crizotinib—JAK3—Immune System—VAV3—hypothyroidism	6.89e-05	0.000194	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—VAV3—hypothyroidism	6.89e-05	0.000194	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—IYD—hypothyroidism	6.89e-05	0.000194	CbGpPWpGaD
Crizotinib—PRKD1—Metabolism—POMC—hypothyroidism	6.89e-05	0.000194	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TRH—hypothyroidism	6.87e-05	0.000193	CbGpPWpGaD
Crizotinib—STK3—Signaling Pathways—POMC—hypothyroidism	6.87e-05	0.000193	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—VAV3—hypothyroidism	6.86e-05	0.000193	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—VAV3—hypothyroidism	6.82e-05	0.000192	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—VAV3—hypothyroidism	6.76e-05	0.00019	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—VAV3—hypothyroidism	6.73e-05	0.000189	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—PRL—hypothyroidism	6.66e-05	0.000188	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TRH—hypothyroidism	6.66e-05	0.000188	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—TRH—hypothyroidism	6.66e-05	0.000187	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—PRL—hypothyroidism	6.64e-05	0.000187	CbGpPWpGaD
Crizotinib—LCK—Platelet activation, signaling and aggregation—IGF1—hypothyroidism	6.62e-05	0.000186	CbGpPWpGaD
Crizotinib—SRC—Focal Adhesion—IGF1—hypothyroidism	6.62e-05	0.000186	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CLTC—hypothyroidism	6.62e-05	0.000186	CbGpPWpGaD
Crizotinib—STK3—Signaling Pathways—IGF1—hypothyroidism	6.61e-05	0.000186	CbGpPWpGaD
Crizotinib—SRC—Integrated Pancreatic Cancer Pathway—IGF1—hypothyroidism	6.59e-05	0.000185	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—AVP—hypothyroidism	6.57e-05	0.000185	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—PRL—hypothyroidism	6.55e-05	0.000184	CbGpPWpGaD
Crizotinib—MAPK7—Signaling by GPCR—POMC—hypothyroidism	6.54e-05	0.000184	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—TSHB—hypothyroidism	6.54e-05	0.000184	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—TSHR—hypothyroidism	6.54e-05	0.000184	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CLTC—hypothyroidism	6.52e-05	0.000184	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—PRL—hypothyroidism	6.52e-05	0.000184	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—SH2B3—hypothyroidism	6.49e-05	0.000183	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TSHR—hypothyroidism	6.49e-05	0.000183	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TSHB—hypothyroidism	6.49e-05	0.000183	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—VAV3—hypothyroidism	6.45e-05	0.000182	CbGpPWpGaD
Crizotinib—CDK7—Disease—PRL—hypothyroidism	6.43e-05	0.000181	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TSHB—hypothyroidism	6.4e-05	0.00018	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TSHR—hypothyroidism	6.4e-05	0.00018	CbGpPWpGaD
Crizotinib—BLK—Immune System—PRL—hypothyroidism	6.39e-05	0.00018	CbGpPWpGaD
Crizotinib—ABCB1—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	6.37e-05	0.000179	CbGpPWpGaD
Crizotinib—FGR—Immune System—PRL—hypothyroidism	6.37e-05	0.000179	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—VAV3—hypothyroidism	6.33e-05	0.000178	CbGpPWpGaD
Crizotinib—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	6.3e-05	0.000177	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CLTC—hypothyroidism	6.19e-05	0.000174	CbGpPWpGaD
Crizotinib—LCK—Immune System—CLTC—hypothyroidism	6.17e-05	0.000174	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—VAV3—hypothyroidism	6.17e-05	0.000173	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—VAV3—hypothyroidism	6.14e-05	0.000173	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TSHB—hypothyroidism	6.13e-05	0.000172	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TSHR—hypothyroidism	6.13e-05	0.000172	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—VAV3—hypothyroidism	6.09e-05	0.000171	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—VAV3—hypothyroidism	6.06e-05	0.000171	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—VAV3—hypothyroidism	6.06e-05	0.00017	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—VAV3—hypothyroidism	6.03e-05	0.00017	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CLTC—hypothyroidism	6.01e-05	0.000169	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TSHB—hypothyroidism	5.94e-05	0.000167	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TSHR—hypothyroidism	5.94e-05	0.000167	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—AVP—hypothyroidism	5.94e-05	0.000167	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—TSHB—hypothyroidism	5.94e-05	0.000167	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—TSHR—hypothyroidism	5.94e-05	0.000167	CbGpPWpGaD
Crizotinib—BLK—Immune System—VAV3—hypothyroidism	5.91e-05	0.000166	CbGpPWpGaD
Crizotinib—FGR—Immune System—VAV3—hypothyroidism	5.89e-05	0.000166	CbGpPWpGaD
Crizotinib—SRC—Platelet activation, signaling and aggregation—IGF1—hypothyroidism	5.86e-05	0.000165	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—ATP5O—hypothyroidism	5.86e-05	0.000165	CbGpPWpGaD
Crizotinib—CYP3A5—Biological oxidations—POMC—hypothyroidism	5.84e-05	0.000164	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—AVP—hypothyroidism	5.81e-05	0.000164	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—SH2B3—hypothyroidism	5.79e-05	0.000163	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—POMC—hypothyroidism	5.76e-05	0.000162	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—POMC—hypothyroidism	5.76e-05	0.000162	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TRH—hypothyroidism	5.72e-05	0.000161	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—SH2B3—hypothyroidism	5.7e-05	0.000161	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—VAV3—hypothyroidism	5.7e-05	0.00016	CbGpPWpGaD
Crizotinib—PTK2—Hemostasis—IGF1—hypothyroidism	5.66e-05	0.000159	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TRH—hypothyroidism	5.64e-05	0.000159	CbGpPWpGaD
Crizotinib—YES1—Hemostasis—IGF1—hypothyroidism	5.58e-05	0.000157	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—VAV3—hypothyroidism	5.54e-05	0.000156	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—IGF1—hypothyroidism	5.54e-05	0.000156	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—IGF1—hypothyroidism	5.54e-05	0.000156	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—TPO—hypothyroidism	5.51e-05	0.000155	CbGpPWpGaD
Crizotinib—SRC—Immune System—CLTC—hypothyroidism	5.46e-05	0.000154	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—SH2B3—hypothyroidism	5.46e-05	0.000154	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—POMC—hypothyroidism	5.46e-05	0.000154	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TRH—hypothyroidism	5.35e-05	0.00015	CbGpPWpGaD
Crizotinib—JAK3—GPCR downstream signaling—POMC—hypothyroidism	5.32e-05	0.00015	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—SH2B3—hypothyroidism	5.29e-05	0.000149	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—IGF1—hypothyroidism	5.25e-05	0.000148	CbGpPWpGaD
Crizotinib—PTK2—Immune System—PRL—hypothyroidism	5.21e-05	0.000147	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—IYD—hypothyroidism	5.2e-05	0.000146	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TRH—hypothyroidism	5.19e-05	0.000146	CbGpPWpGaD
Crizotinib—YES1—Immune System—PRL—hypothyroidism	5.14e-05	0.000145	CbGpPWpGaD
Crizotinib—CYP3A4—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	5.11e-05	0.000144	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TSHB—hypothyroidism	5.1e-05	0.000143	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TSHR—hypothyroidism	5.1e-05	0.000143	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TSHB—hypothyroidism	5.03e-05	0.000141	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TSHR—hypothyroidism	5.03e-05	0.000141	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—VAV3—hypothyroidism	5e-05	0.000141	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—POMC—hypothyroidism	4.99e-05	0.000141	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—VAV3—hypothyroidism	4.99e-05	0.00014	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—VAV3—hypothyroidism	4.91e-05	0.000138	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—PRL—hypothyroidism	4.88e-05	0.000137	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CLTC—hypothyroidism	4.86e-05	0.000137	CbGpPWpGaD
Crizotinib—JAK3—Signaling by GPCR—POMC—hypothyroidism	4.83e-05	0.000136	CbGpPWpGaD
Crizotinib—PTK2—Immune System—VAV3—hypothyroidism	4.82e-05	0.000136	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—PRL—hypothyroidism	4.82e-05	0.000136	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—IGF1—hypothyroidism	4.8e-05	0.000135	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—VAV3—hypothyroidism	4.79e-05	0.000135	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TSHB—hypothyroidism	4.77e-05	0.000134	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TSHR—hypothyroidism	4.77e-05	0.000134	CbGpPWpGaD
Crizotinib—YES1—Immune System—VAV3—hypothyroidism	4.76e-05	0.000134	CbGpPWpGaD
Crizotinib—TYK2—Immune System—PRL—hypothyroidism	4.73e-05	0.000133	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TSHB—hypothyroidism	4.63e-05	0.00013	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TSHR—hypothyroidism	4.63e-05	0.00013	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—AVP—hypothyroidism	4.62e-05	0.00013	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CLTC—hypothyroidism	4.55e-05	0.000128	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—SH2B3—hypothyroidism	4.54e-05	0.000128	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—VAV3—hypothyroidism	4.51e-05	0.000127	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—SH2B3—hypothyroidism	4.48e-05	0.000126	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—VAV3—hypothyroidism	4.46e-05	0.000125	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ATP5O—hypothyroidism	4.42e-05	0.000124	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—VAV3—hypothyroidism	4.42e-05	0.000124	CbGpPWpGaD
Crizotinib—TYK2—Immune System—VAV3—hypothyroidism	4.38e-05	0.000123	CbGpPWpGaD
Crizotinib—TYK2—Disease—PRL—hypothyroidism	4.37e-05	0.000123	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—POMC—hypothyroidism	4.36e-05	0.000123	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—PRL—hypothyroidism	4.29e-05	0.000121	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—AVP—hypothyroidism	4.29e-05	0.000121	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—SH2B3—hypothyroidism	4.25e-05	0.00012	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—PRL—hypothyroidism	4.23e-05	0.000119	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TRH—hypothyroidism	4.2e-05	0.000118	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—IGF1—hypothyroidism	4.2e-05	0.000118	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—IGF1—hypothyroidism	4.16e-05	0.000117	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—TPO—hypothyroidism	4.16e-05	0.000117	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—IGF1—hypothyroidism	4.14e-05	0.000117	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—SH2B3—hypothyroidism	4.12e-05	0.000116	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—PRL—hypothyroidism	4.05e-05	0.000114	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—VAV3—hypothyroidism	4e-05	0.000113	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CLTC—hypothyroidism	3.99e-05	0.000112	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—VAV3—hypothyroidism	3.97e-05	0.000112	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—POMC—hypothyroidism	3.95e-05	0.000111	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TRH—hypothyroidism	3.93e-05	0.000111	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—PRL—hypothyroidism	3.93e-05	0.000111	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—VAV3—hypothyroidism	3.92e-05	0.00011	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—hypothyroidism	3.9e-05	0.00011	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—IGF1—hypothyroidism	3.9e-05	0.00011	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—POMC—hypothyroidism	3.86e-05	0.000109	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—AVP—hypothyroidism	3.85e-05	0.000108	CbGpPWpGaD
Crizotinib—LYN—Immune System—PRL—hypothyroidism	3.83e-05	0.000108	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—AVP—hypothyroidism	3.83e-05	0.000108	CbGpPWpGaD
Crizotinib—ABL1—Immune System—PRL—hypothyroidism	3.81e-05	0.000107	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—IGF1—hypothyroidism	3.8e-05	0.000107	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—AVP—hypothyroidism	3.77e-05	0.000106	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TSHB—hypothyroidism	3.75e-05	0.000105	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TSHR—hypothyroidism	3.75e-05	0.000105	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—VAV3—hypothyroidism	3.75e-05	0.000105	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—IGF1—hypothyroidism	3.72e-05	0.000105	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—VAV3—hypothyroidism	3.63e-05	0.000102	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—VAV3—hypothyroidism	3.63e-05	0.000102	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—AVP—hypothyroidism	3.61e-05	0.000102	CbGpPWpGaD
Crizotinib—JAK2—Immune System—PRL—hypothyroidism	3.59e-05	0.000101	CbGpPWpGaD
Crizotinib—LYN—Immune System—VAV3—hypothyroidism	3.55e-05	9.98e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CLTC—hypothyroidism	3.53e-05	9.93e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—VAV3—hypothyroidism	3.53e-05	9.93e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TSHR—hypothyroidism	3.51e-05	9.87e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TSHB—hypothyroidism	3.51e-05	9.87e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—AVP—hypothyroidism	3.5e-05	9.85e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—AVP—hypothyroidism	3.5e-05	9.85e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TRH—hypothyroidism	3.45e-05	9.7e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—IGF1—hypothyroidism	3.41e-05	9.6e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—PRL—hypothyroidism	3.37e-05	9.48e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—SH2B3—hypothyroidism	3.34e-05	9.4e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—PRL—hypothyroidism	3.32e-05	9.35e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—VAV3—hypothyroidism	3.32e-05	9.34e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—PRL—hypothyroidism	3.31e-05	9.32e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—IYD—hypothyroidism	3.2e-05	9.01e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—PRL—hypothyroidism	3.15e-05	8.87e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—PRL—hypothyroidism	3.14e-05	8.84e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—SH2B3—hypothyroidism	3.13e-05	8.8e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—VAV3—hypothyroidism	3.12e-05	8.77e-05	CbGpPWpGaD
Crizotinib—ABCB1—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	3.08e-05	8.65e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—VAV3—hypothyroidism	3.07e-05	8.65e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TSHB—hypothyroidism	3.07e-05	8.64e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TSHR—hypothyroidism	3.07e-05	8.64e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—POMC—hypothyroidism	3.07e-05	8.63e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—PRL—hypothyroidism	3.06e-05	8.61e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TRH—hypothyroidism	3.05e-05	8.58e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—IGF1—hypothyroidism	3.02e-05	8.5e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—AVP—hypothyroidism	3e-05	8.45e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—AVP—hypothyroidism	2.96e-05	8.33e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—VAV3—hypothyroidism	2.92e-05	8.21e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—VAV3—hypothyroidism	2.91e-05	8.18e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—PRL—hypothyroidism	2.9e-05	8.16e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—POMC—hypothyroidism	2.85e-05	8.03e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—VAV3—hypothyroidism	2.83e-05	7.97e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—AVP—hypothyroidism	2.81e-05	7.91e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—PRL—hypothyroidism	2.78e-05	7.83e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—IGF1—hypothyroidism	2.74e-05	7.72e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—SH2B3—hypothyroidism	2.74e-05	7.7e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—AVP—hypothyroidism	2.73e-05	7.67e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ATP5O—hypothyroidism	2.72e-05	7.66e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TSHB—hypothyroidism	2.72e-05	7.65e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TSHR—hypothyroidism	2.72e-05	7.65e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Biological oxidations—POMC—hypothyroidism	2.71e-05	7.64e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—VAV3—hypothyroidism	2.57e-05	7.24e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—PRL—hypothyroidism	2.57e-05	7.23e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—TPO—hypothyroidism	2.56e-05	7.2e-05	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—POMC—hypothyroidism	2.56e-05	7.2e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—TSHB—hypothyroidism	2.55e-05	7.17e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—POMC—hypothyroidism	2.54e-05	7.16e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—POMC—hypothyroidism	2.51e-05	7.05e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PRL—hypothyroidism	2.48e-05	6.97e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—IGF1—hypothyroidism	2.45e-05	6.88e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—SH2B3—hypothyroidism	2.42e-05	6.82e-05	CbGpPWpGaD
Crizotinib—ABCB1—Transmembrane transport of small molecules—AVP—hypothyroidism	2.42e-05	6.81e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—IGF1—hypothyroidism	2.41e-05	6.79e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—POMC—hypothyroidism	2.4e-05	6.75e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—POMC—hypothyroidism	2.33e-05	6.55e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—POMC—hypothyroidism	2.33e-05	6.54e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PRL—hypothyroidism	2.32e-05	6.53e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IGF1—hypothyroidism	2.31e-05	6.49e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—VAV3—hypothyroidism	2.29e-05	6.45e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3C2A—hypothyroidism	2.27e-05	6.39e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IGF1—hypothyroidism	2.24e-05	6.3e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—AVP—hypothyroidism	2.21e-05	6.21e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—VAV3—hypothyroidism	2.15e-05	6.04e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—AVP—hypothyroidism	2.07e-05	5.82e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PRL—hypothyroidism	2.03e-05	5.72e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—POMC—hypothyroidism	2e-05	5.62e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—POMC—hypothyroidism	1.97e-05	5.54e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—TSHB—hypothyroidism	1.92e-05	5.41e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IGF1—hypothyroidism	1.92e-05	5.4e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—SLC5A5—hypothyroidism	1.91e-05	5.37e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IGF1—hypothyroidism	1.89e-05	5.33e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—VAV3—hypothyroidism	1.88e-05	5.29e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—POMC—hypothyroidism	1.87e-05	5.25e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—POMC—hypothyroidism	1.81e-05	5.1e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—AVP—hypothyroidism	1.81e-05	5.09e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PRL—hypothyroidism	1.8e-05	5.06e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IGF1—hypothyroidism	1.8e-05	5.05e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IGF1—hypothyroidism	1.74e-05	4.91e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3C2A—hypothyroidism	1.71e-05	4.83e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—VAV3—hypothyroidism	1.66e-05	4.68e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—AVP—hypothyroidism	1.6e-05	4.51e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—POMC—hypothyroidism	1.47e-05	4.13e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—SLC5A5—hypothyroidism	1.44e-05	4.05e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IGF1—hypothyroidism	1.41e-05	3.97e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—POMC—hypothyroidism	1.37e-05	3.86e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IGF1—hypothyroidism	1.32e-05	3.72e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—POMC—hypothyroidism	1.2e-05	3.39e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—TSHB—hypothyroidism	1.19e-05	3.34e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IGF1—hypothyroidism	1.16e-05	3.26e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—POMC—hypothyroidism	1.07e-05	3e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3C2A—hypothyroidism	1.06e-05	2.97e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IGF1—hypothyroidism	1.02e-05	2.88e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—POMC—hypothyroidism	9.99e-06	2.81e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SLC5A5—hypothyroidism	8.87e-06	2.5e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—POMC—hypothyroidism	7.54e-06	2.12e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—POMC—hypothyroidism	4.64e-06	1.31e-05	CbGpPWpGaD
